Connor, Clark & Lunn Investment Management (CC&L)
IONS icon

Connor, Clark & Lunn Investment Management (CC&L)’s Ionis Pharmaceuticals IONS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.3M Sell
684,236
-189,853
-22% -$14.3M 0.1% 182
2026
Q1 		$65.6M Sell
874,089
-202,281
-19% -$16M 0.15% 144
2025
Q4 		$85.2M Buy
1,076,370
+198,215
+23% +$14.9M 0.22% 96
2025
Q3 		$57.4M Buy
878,155
+612,362
+230% +$29.9M 0.18% 105
2025
Q2 		$10.5M Buy
265,793
+136,520
+106% +$4.47M 0.04% 389
2025
Q1 		$3.9M Buy
129,273
+3,884
+3% +$127K 0.02% 566
2024
Q4 		$4.38M Buy
125,389
+107,648
+607% +$4.02M 0.02% 516
2024
Q3 		$711K Sell
17,741
-26,515
-60% -$1.23M ﹤0.01% 988
2024
Q2 		$2.11M Buy
+44,256
New +$1.82M 0.01% 640
2024
Q1 		– Sell
-127,954
Closed -$6.47M – 1610
2023
Q4 		$6.47M Sell
127,954
-1,858
-1% -$89K 0.03% 354
2023
Q3 		$5.89M Sell
129,812
-68,696
-35% -$2.83M 0.03% 356
2023
Q2 		$8.14M Sell
198,508
-80,250
-29% -$3.08M 0.04% 295
2023
Q1 		$9.96M Buy
278,758
+48,181
+21% +$1.81M 0.05% 255
2022
Q4 		$8.71M Buy
230,577
+1,516
+0.7% +$63.8K 0.05% 246
2022
Q3 		$10.1M Buy
229,061
+97,078
+74% +$4.09M 0.07% 201
2022
Q2 		$4.89M Sell
131,983
-25,210
-16% -$951K 0.03% 317
2022
Q1 		$5.82M Buy
157,193
+44,668
+40% +$1.46M 0.03% 302
2021
Q4 		$3.42M Buy
112,525
+76,989
+217% +$2.42M 0.02% 409
2021
Q3 		$1.19M Buy
+35,536
New +$1.34M 0.01% 613
2021
Q2 		– Sell
-51,579
Closed -$2.32M – 1032
2021
Q1 		$2.32M Buy
+51,579
New +$2.88M 0.01% 525
2019
Q4 		– Sell
-18,825
Closed -$1.13M – 1010
2019
Q3 		$1.13M Buy
+18,825
New +$1.23M 0.01% 520
2018
Q3 		– Sell
-29,150
Closed -$1.22M – 1027
2018
Q2 		$1.22M Buy
+29,150
New +$1.29M 0.01% 572
2015
Q4 		– Sell
-5,900
Closed -$238K – 837
2015
Q3 		$238K Buy
+5,900
New +$305K ﹤0.01% 623
2014
Q2 		– Sell
-8,935
Closed -$426K – 586
2014
Q1 		$426K Sell
8,935
-42,100
-82% -$2.04M ﹤0.01% 509
2013
Q4 		$2.16M Sell
51,035
-2,900
-5% -$103K 0.02% 252
2013
Q3 		$2.08M Buy
53,935
+6,850
+15% +$205K 0.02% 190
2013
Q2 		$1.33M Buy
+47,085
New +$1M 0.01% 233

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s IONS Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Ionis Pharmaceuticals (IONS) stake by 22% in Q2 2026, selling an estimated $14.3M and leaving 684,236 shares worth $54.3M. The position accounts for 0.1% of the portfolio, ranked #182.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in IONS in Q2 2013 and has held it in 27 quarters since. The position peaked at $85.2M in Q4 2025. 512 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 684,236 shares of Ionis Pharmaceuticals worth $54.3M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 189,853 Ionis Pharmaceuticals shares in Q2 2026, an estimated $14.3M.
  • Ionis Pharmaceuticals made up 0.1% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #182 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Ionis Pharmaceuticals position peaked at $85.2M in Q4 2025.
  • 512 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.